Skip to main content
. 2024 Jul 26;14(7):e084933. doi: 10.1136/bmjopen-2024-084933

Table 1. Participant characteristics overall and stratified by sex.

Total population (n=988) Women (n=530) Men (n=458) P value
MED (IQR) or n (%) MED (IQR) or n (%) MED (IQR) or n (%)
Age (years) 50.4 (41.4–59.5) 51.2 (42.1–59.3) 49.9 (41.0–59.8) 0.437
Marital status <0.001
 Married/living with partner 740 (74.9) 374 (70.6) 366 (79.9)
 Single/divorced/separated/widowed 248 (25.1) 156 (29.4) 92 (20.1)
Employment status 0.060
 Employed 657 (66.5) 338 (63.8) 319 (69.7)
 Unemployed/at home/retired/unable to work 331 (33.5) 192 (36.2) 139 (30.3)
Family history of CVD or diabetes <0.001
 No 178 (18.0) 84 (15.8) 94 (20.5)
 Yes 671 (67.9) 394 (74.3) 277 (60.5)
 Unknown 139 (14.1) 52 (9.8) 87 (19.0)
Use of antihypertensive, diabetes and/or lipid-lowering medication 0.060
 No 724 (73.3) 402 (75.8) 322 (70.3)
 Yes 264 (26.7) 128 (24.2) 136 (29.7)
Smoking status <0.01
 Current smoker 121 (12.2) 58 (10.9) 63 (13.8)
 Former smoker 275 (27.8) 130 (24.5) 145 (31.7)
 Non-smoker 592 (59.9) 342 (64.5) 250 (54.6)
Total sleep period (min) 410.9 (373.3–444.8) 420.1 (390.5–451.7) 391.7 (360.2–431.7) <0.001
Energy intake (kcal/day) 2359 (1858–2965) 2131 (1734–2633) 2653 (2119–3264) <0.001
PWV (m/s) 7.75 (6.85–9.00) 7.53 (6.75–8.70) 7.95 (7.05–9.25) <0.001
Average 24 hours acceleration (mg) 25.53 (21.26–30.40) 26.25 (22.21–30.84) 24.77 (20.50–29.64) <0.001
Intensity gradient −2.64 (−2.76–−2.51) −2.66 (−2.78–−2.52) −2.61 (−2.74–−2.47) <0.001
M0.5 (g) 105.75 (85.06–141.95) 107.36 (85.67–141.30) 104.19 (84.83–142.54) 0.761
Median SB bout length (s) 1900 (1700–2100) 1850 (1700–2050) 1900 (1700–2150) <0.05
Median MVPA bout length (s) 300 (200–450) 300 (200–400) 300 (200–450) 0.370
Number of SB bouts >30 min 5.67 (4.67–6.67) 5.50 (4.33–6.33) 6.00 (5.00–7.00) <0.001
Proportion SB >60 min (%) 25.59 (18.69–33.49) 24.46 (16.67–32.33) 27.14 (20.34–34.88) <0.001
Scaling exponent alpha (<90 min) 0.96 (0.91–1.02) 0.96 (0.92–1.02) 0.96 (0.90–1.02) 0.164
Scaling exponent alpha (>120 min) 0.98 (0.87–1.07) 0.99 (0.89–1.09) 0.96 (0.84–1.06) <0.001
Autocorrelation at lag 24 hours 0.13 (0.10–0.17) 0.14 (0.11–0.18) 0.12 (0.09–0.15) <0.001
Lempel-Ziv complexity 0.17 (0.15–0.20) 0.18 (0.16–0.21) 0.16 (0.13–0.19) <0.001
Sample entropy −0.39 (−0.64–0.15) −0.38 (−0.65–0.14) −0.42 (−0.64–0.16) 0.604
Beta-carotene (μg/day) 4947 (3328–7271) 5052 (3444–7534) 4675 (3222–7000) 0.061
Vitamin A (retinol, μg/day) 465.8 (329.1–640.1) 419.0 (304.6–572.5) 530.5 (366.9–722.8) <0.001
Vitamin C (ascorbic acid, mg/day) 145.2 (100.2–201.9) 150.4 (103.0–206.9) 140.6 (97.8–199.1) 0.095
Vitamin E (tocopherols, mg/day) 18.19 (13.59–25.15) 16.78 (13.03–22.51) 19.93 (14.40–28.29) <0.001
Polyphenols (mg/day) 2484 (1749–3379) 2490 (1755–3331) 2483 (1745–3433) 0.766
Zinc (mg/day) 12.20 (9.47–15.66) 11.13 (8.90–13.63) 13.91 (10.59–17.18) <0.001
Selenium (μg/day) 91.57 (71.63–111.92) 83.97 (67.87–103.11) 100.0 (79.01–122.0) <0.001

Data are presented as n (%) for categorical variables and median (IQR) for non-normally distributed continuous variables. P- values represent a test of group differences by sex performed using χ2chi-square tests or Kruskal-Wallis tests as appropriate. Bold font signifies statistically significant difference between women and men (pp<0.05).disease; M0.5 acceleration above which the most activemin of the day were accumulated;vigorous ; Proportionof total SB time accumulated in bouts longer thanmin; ; .

CVDcardiovascular diseaseM0.5average acceleration above which the most active 30 min of the day were accumulatedMVPAmoderate-to-vigorous physical activityProportion SBproportion of total SB time accumulated in bouts longer than 60 minPWVpulse wave velocitySBsedentary behaviour